CN113301885A - 新型组合物 - Google Patents

新型组合物 Download PDF

Info

Publication number
CN113301885A
CN113301885A CN201980085068.5A CN201980085068A CN113301885A CN 113301885 A CN113301885 A CN 113301885A CN 201980085068 A CN201980085068 A CN 201980085068A CN 113301885 A CN113301885 A CN 113301885A
Authority
CN
China
Prior art keywords
aqueous solution
acid
solution composition
composition according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980085068.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·耶热克
D·格林
S·豪威尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1821149.0A external-priority patent/GB201821149D0/en
Priority claimed from GBGB1911581.5A external-priority patent/GB201911581D0/en
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of CN113301885A publication Critical patent/CN113301885A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980085068.5A 2018-12-21 2019-12-20 新型组合物 Pending CN113301885A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1821149.0A GB201821149D0 (en) 2018-12-21 2018-12-21 Novel composition
GB1821149.0 2018-12-21
GB1911581.5 2019-08-13
GBGB1911581.5A GB201911581D0 (en) 2019-08-13 2019-08-13 Novel composition
PCT/GB2019/053655 WO2020128507A1 (en) 2018-12-21 2019-12-20 Novel composition

Publications (1)

Publication Number Publication Date
CN113301885A true CN113301885A (zh) 2021-08-24

Family

ID=69104798

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980085068.5A Pending CN113301885A (zh) 2018-12-21 2019-12-20 新型组合物
CN201980085263.8A Pending CN113271922A (zh) 2018-12-21 2019-12-20 新型组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980085263.8A Pending CN113271922A (zh) 2018-12-21 2019-12-20 新型组合物

Country Status (9)

Country Link
US (2) US12239685B2 (https=)
EP (2) EP3897573A1 (https=)
JP (2) JP7421556B2 (https=)
KR (1) KR20210114000A (https=)
CN (2) CN113301885A (https=)
AU (1) AU2019411551A1 (https=)
BR (1) BR112021011753A2 (https=)
CA (1) CA3124529A1 (https=)
WO (2) WO2020128507A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239685B2 (en) 2018-12-21 2025-03-04 Arecor Limited Composition
WO2020229369A1 (en) * 2019-05-10 2020-11-19 Xellia Pharmaceuticals Aps Daptomycin aqueous formulations
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN116726145A (zh) * 2022-03-04 2023-09-12 海南普利制药股份有限公司 一种稳定的酯肽类药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20110172167A1 (en) * 2009-09-17 2011-07-14 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20170348382A1 (en) * 2014-12-16 2017-12-07 Dr. Reddy's Laboratories Limited Lyophilized injectable compositions of daptomycin
WO2018073269A1 (en) * 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
CN100421726C (zh) 2006-03-06 2008-10-01 南京凯瑞尔纳米生物技术有限公司 包含有肽类药物的纳米复合物滴眼液及其制备方法
RU2770366C2 (ru) * 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
US12239685B2 (en) 2018-12-21 2025-03-04 Arecor Limited Composition
WO2020229369A1 (en) 2019-05-10 2020-11-19 Xellia Pharmaceuticals Aps Daptomycin aqueous formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20110172167A1 (en) * 2009-09-17 2011-07-14 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20170348382A1 (en) * 2014-12-16 2017-12-07 Dr. Reddy's Laboratories Limited Lyophilized injectable compositions of daptomycin
WO2018073269A1 (en) * 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin

Also Published As

Publication number Publication date
CN113271922A (zh) 2021-08-17
JP7421556B2 (ja) 2024-01-24
BR112021011753A2 (pt) 2021-08-31
EP3897572A1 (en) 2021-10-27
CA3124529A1 (en) 2020-06-25
AU2019411551A1 (en) 2021-06-24
JP2022514597A (ja) 2022-02-14
JP2022514858A (ja) 2022-02-16
US12239685B2 (en) 2025-03-04
US20220072091A1 (en) 2022-03-10
WO2020128506A1 (en) 2020-06-25
WO2020128507A1 (en) 2020-06-25
EP3897573A1 (en) 2021-10-27
KR20210114000A (ko) 2021-09-17
US20220072090A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CN113301885A (zh) 新型组合物
KR101530942B1 (ko) 안정한 보르테조밉 포뮬레이션
US20120172808A1 (en) Stable Bortezomib Formulations
JP7220664B2 (ja) 液体医薬組成物
JP2000247903A (ja) 長期安定化製剤
JP2023058632A (ja) 液体医薬組成物
CN111511351A (zh) 新型组合物
CN1264569C (zh) 无蛋白制剂
EP2644189B1 (en) Stable bortezomib formulations
CN101578106A (zh) Hgf制剂
KR101699677B1 (ko) 고나도트로핀을 위한 제제
CN113453661A (zh) 新组合物
US20130149293A1 (en) Stable compositions of factor ix
CA2726232A1 (en) Stable formulation of a therapeutic protein
CN121910662A (zh) 包含抗体的新组合物
US10576088B2 (en) Compositions comprising finafloxacin and Tris
US20100316592A1 (en) AQUEOUS PREPARATION COMPRISING eMIP AS ACTIVE INGREDIENT
JP2010275259A (ja) 均一、かつ安定なラタノプロスト点眼液剤組成物
JP2025522933A (ja) メルファランを含む安定した液体医薬組成物
JP2019147756A (ja) 安定な新規赤血球産生刺激タンパク質製剤
NZ733837B2 (en) Pharmaceutical composition comprising plasminogen and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination